But Wnt has lagged behind. No specifi c Wnt pathway inhibitor has yet entered clinical testing, even though more than 80% of colorectal cancers are driven by Wnt pathway mutations.
"For many, many years the rate of progress was extremely slow in developing anything resembling a therapeutic for this pathway," said Randall Moon, Ph.D., of the University of Washington in Seattle. The lack of progress, in large part, was due to the lack of obvious enzyme targets in the pathway, which was not considered "druggable."
Several new discoveries have changed that. "The idea that this is a nondruggable pathway is, at this point, thrown out the window," Moon said. Several academic groups have published proof-of-concept reports on small-molecule Wnt pathway inhibitors, and a few biotech companies (along with an unknown number of pharmaceutical companies) are actively developing these and other compounds. At the same time, the number of tumor types known to be dependent on Wnt signaling, in addition to colorectal cancer, has been growing. The list includes pancreatic cancer, lung cancer, prostate cancer, and leukemia.
At least two companies have publicly disclosed plans to move Wnt pathway inhibitors into the clinic by early 2010. Genentech also is involved, although the company declined an interview request because "there is very little we can discuss publicly," according to Over the last 15 years, the main components of canonical Wnt signaling (signaling that depends on ß-catenin), have been worked out. Without secreted Wnt proteins, ß-catenin in the cytoplasm joins APC and Axin in a "destruction complex" that enables ß-catenin's subsequent degradation. ß-Catenin target genes stay turned off. But when Wnt proteins bind to their receptors on the cell surface, the destruction complex is inactivated and ß-catenin goes to the nucleus, where it interacts with T-cell factor (TCF) transcription factors, Germantown, Md., has compounds that act on the proteasome, the enzyme complex that breaks down cellular proteins, causing "a very dramatic and very rapid reduction in ß-catenin protein," said Avalon CEO Kenneth Carter, Ph.D. The company hopes to begin clinical trials by 2010.
New Tools, New Targets
In other work, researchers have found two new ways to block Wnt signaling, both upstream and downstream of APC. In the February 2009 issue of Nature Chemical Biology , Lum's group in Dallas reported a class of small-molecule compounds that specifi cally target the protein porcupine, which is essential for Wnt secretion. These compounds "argue that you can successfully target pathways like the Wnt pathway at the level of ligand production," Lum said.
Lum is using the compounds to probe the function of various Wnt ligands. There are 19 Wnt genes in the human genome, and some may contribute to cancer via unknown pathways. Until now "we've been looking … from a very small window, which is Wnt/ß-catenin signaling," Lum said. "Wnt proteins that control other signaling pathways may be playing just as potentially important roles in promoting cancer cell growth."
Lum's other new compound class (also reported in Nature Chemical Biology ) blocks downstream Wnt/ß-catenin signaling by binding to Axin proteins, which are part of the ß-catenin destruction complex. The compounds stabilize Axin and essentially build a new destruction complex to eliminate ß-catenin, even in the presence of APC mutations. Lum said that in cancer cell lines and other models with decreased APC function, "in every case these compounds seem to bring down ß-catenin levels and this activation of target genes associated with colorectal cancer." His group has provisional patents for these compounds but has not formed a relationship with a drug or biotechnology company to develop them.
Toxicity Pitfalls
Lum's group also found that the negative effects of these compounds on normal cells N E W S were reversible. That's important because the Wnt pathway is critical for tissue regeneration and for the ability of stem cells in the bone marrow and gut to self-renew. Wnt pathway inhibitors could therefore have serious and lasting side effects, including anemia and immune suppression, as well as damage to the intestinal tract. "It is a complete black box as to what will happen to an adult mammal when this pathway is shut down," said Lum.
His experiments offer some clues, though. When he added the drugs to the aquarium water of zebrafi sh, after cutting off part of the fi shes ' tailfi ns, the compounds blocked tailfi n regeneration as Wnt pathway inhibitors should. But after the chemicals were removed from the water, the fi sh regrew their fi ns, showing that the defect was temporary. And though drug treatment led to gastrointestinal damage and caused the fi sh to lose energy and appetite, these effects at least partly disappeared when treatment ended. "The [gastrointestinal] tract does not look great, but, remarkably, after we removed these chemicals, the fi sh not only regenerate tails but they feed and thrive," said Lum.
Side effects in humans are inevitable, though. "I'm not sure at what [dosage] level you'll see these effects, but they will occur," said Polakis at the 2007 meeting. Moon speculated that toxicity in humans might be manageable as long as the pathway isn't blocked. "Even if you knock down signaling 75%, the remaining 25% might be fi ne for [stem cells] to get by on," he said. But Wnt pathway inhibitors may not cause frank tumor regression, even at high doses. "With targeted agents like this … I think there's a question about whether any of these agents are going to lead to sort of cytotoxic levels of tumor regression," said Carter, who added that these drugs will probably be used in combination with others.
Another challenge for Wnt researchers is pathway variability across tumor types. Because Wnt signaling is so context dependent, tumor models will have to closely mimic the human situation to accurately predict response. "It's important for people to realize that the pathway is not identical between all cell types," Moon said.
Despite pitfalls, researchers and companies are moving steadily forward with Wnt pathway inhibitors. And at the very least, Wnt drugs will get a thorough testing in clinical trials. "We will see actual therapies," predicted Moon.
